Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

In vitro efficacy of next-generation dihydrotriazines and biguanides against babesiosis and malaria parasites.

Autor: Vydyam P; Departments of Internal Medicine (Section of Infectious Diseases), Microbial Pathogenesis, and Pathology, Yale School of Medicine, New Haven, Connecticut, USA., Chand M; Departments of Internal Medicine (Section of Infectious Diseases), Microbial Pathogenesis, and Pathology, Yale School of Medicine, New Haven, Connecticut, USA., Gihaz S; Departments of Internal Medicine (Section of Infectious Diseases), Microbial Pathogenesis, and Pathology, Yale School of Medicine, New Haven, Connecticut, USA., Renard I; Departments of Internal Medicine (Section of Infectious Diseases), Microbial Pathogenesis, and Pathology, Yale School of Medicine, New Haven, Connecticut, USA., Heffernan GD; Jacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA., Jacobus LR; Jacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA., Jacobus DP; Jacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA., Saionz KW; Jacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA., Shah R; Jacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA., Shieh H-M; Jacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA., Terpinski J; Jacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA., Zhao W; Jacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA., Cornillot E; Institut de Biologie Computationnelle (IBC), and Institut de Recherche en Cancérologie de Montpellier (IRCM - INSERM U1194), Institut régional du Cancer Montpellier (ICM) & Université de Montpellier, Montpellier, France., Ben Mamoun C; Departments of Internal Medicine (Section of Infectious Diseases), Microbial Pathogenesis, and Pathology, Yale School of Medicine, New Haven, Connecticut, USA.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2024 Sep 04; Vol. 68 (9), pp. e0042324. Date of Electronic Publication: 2024 Aug 13.

In Vivo Efficacy and Pharmacokinetics of the 2-Aminomethylphenol Antimalarial JPC-3210 in the Aotus Monkey-Human Malaria Model.

Autor: McCallum FJ; Department of Drug Evaluation, Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI), Brisbane, Queensland, Australia., Birrell GW; Department of Drug Evaluation, Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI), Brisbane, Queensland, Australia., Chavchich M; Department of Drug Evaluation, Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI), Brisbane, Queensland, Australia., Harris I; Department of Drug Evaluation, Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI), Brisbane, Queensland, Australia., Obaldia N 3rd; Gorgas Memorial Institute of Health Studies (GMIHS), Panama City, Republic of Panama., Van Breda K; Department of Drug Evaluation, Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI), Brisbane, Queensland, Australia., Heffernan GD; Jacobus Pharmaceutical Company, Inc (JPC), Princeton, New Jersey, USA., Jacobus DP; Jacobus Pharmaceutical Company, Inc (JPC), Princeton, New Jersey, USA., Shanks D; Department of Drug Evaluation, Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI), Brisbane, Queensland, Australia., Edstein MD; Department of Drug Evaluation, Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI), Brisbane, Queensland, Australia Mike.Edstein@defence.gov.au.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2020 Feb 21; Vol. 64 (3). Date of Electronic Publication: 2020 Feb 21 (Print Publication: 2020).

Characterization of the Preclinical Pharmacology of the New 2-Aminomethylphenol, JPC-3210, for Malaria Treatment and Prevention.

Autor: Birrell GW; Department of Drug Evaluation, Australian Army Malaria Institute (AMI), Brisbane, Queensland, Australia., Heffernan GD; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Schiehser GA; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Anderson J; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Ager AL; University of Miami, Miami, Florida, USA., Morales P; Mannheimer Foundation, Inc., Homestead, Florida, USA., MacKenzie D; Department of Drug Evaluation, Australian Army Malaria Institute (AMI), Brisbane, Queensland, Australia., van Breda K; Department of Drug Evaluation, Australian Army Malaria Institute (AMI), Brisbane, Queensland, Australia., Chavchich M; Department of Drug Evaluation, Australian Army Malaria Institute (AMI), Brisbane, Queensland, Australia., Jacobus LR; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Shanks GD; Department of Drug Evaluation, Australian Army Malaria Institute (AMI), Brisbane, Queensland, Australia., Jacobus DP; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Edstein MD; Department of Drug Evaluation, Australian Army Malaria Institute (AMI), Brisbane, Queensland, Australia Mike.Edstein@defence.gov.au.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2018 Mar 27; Vol. 62 (4). Date of Electronic Publication: 2018 Mar 27 (Print Publication: 2018).

JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium.

Autor: Birrell GW; Department of Drug Evaluation, Australian Army Malaria Institute, Enoggera, Brisbane, Queensland, Australia., Chavchich M; Department of Drug Evaluation, Australian Army Malaria Institute, Enoggera, Brisbane, Queensland, Australia., Ager AL; University of Miami, Miami, Florida, USA., Shieh HM; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Heffernan GD; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Zhao W; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Krasucki PE; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Saionz KW; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Terpinski J; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Schiehser GA; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Jacobus LR; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Shanks GD; Department of Drug Evaluation, Australian Army Malaria Institute, Enoggera, Brisbane, Queensland, Australia., Jacobus DP; Jacobus Pharmaceutical Company, Princeton, New Jersey, USA., Edstein MD; Department of Drug Evaluation, Australian Army Malaria Institute, Enoggera, Brisbane, Queensland, Australia Mike.Edstein@defence.gov.au.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2015 Jan; Vol. 59 (1), pp. 170-7. Date of Electronic Publication: 2014 Oct 20.